Attached files

file filename
10-Q - QUARTERLY REPORT - Cellular Biomedicine Group, Inc.cbmg_10q.htm
EX-31.1 - CERTIFICATION - Cellular Biomedicine Group, Inc.cbmg_ex311.htm
EX-10.3 - U.S. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE NONEXCLUSIVE PATENT AAV5 LICENSE - Cellular Biomedicine Group, Inc.cbmg_ex103.htm
EX-10.2 - CHINA MERCHANTS BANK APPROVAL OF A CREDIT LINE OF UP TO RMB 30 MILLION TO SBM SH - Cellular Biomedicine Group, Inc.cbmg_ex102.htm
EX-10.1 - NANJING BANK APPROVAL OF A CREDIT LINE OF UP TO RMB 30 MILLION TO CBMG WUXI - Cellular Biomedicine Group, Inc.cbmg_ex101.htm

Exhibit 32.1

 

CERTIFICATION

 

In connection with the quarterly report of Cellular Biomedicine Group, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission (the “Report”), I, Tony (Bizuo) Liu, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

 

 

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. 

  

Date: August 12, 2020

By:

/s/ Tony (Bizuo) Liu

 

 

 

Tony (Bizuo) Liu

 

 

 

Chief Executive Officer and Chief Financial Officer

 

 

 

(Principal Executive Officer and Principal Financial and Accounting Officer)